Does XXXX improve both @entity308 and @entity191 ? A pilot randomized trial.

@entity1 @entity308 @entity905 @entity935 @entity9021 @entity191 @entity750
Some of the selective @entity750 reuptake inhibitors (SSRI)-induced motor side effects are mediated by stimulating 5-HT2 receptors in the basal ganglia, probably because @entity750 inhibits the subsequent neuronal @entity935 release. We hypothesized that @entity9021 , a @entity750 2 antagonist/reuptake inhibitor (SARI) that selectively blocks 5-HT2 receptors, could disrupt the aforementioned inhibitory pathway. Therefore, increased @entity935 levels in the postsynaptic milieu and an improvement in the motor symptoms in @entity308 @entity1 with @entity191 ( @entity191 ) should be observed. This study was designed to determine whether @entity9021 has a dual activity as an antidepressant and as an agent capable of reducing the extrapyramidal symptoms in @entity308 @entity191 @entity1 . @entity308 @entity1 with @entity191 were randomly assigned to 2 therapeutic groups: @entity9021 or @entity905 . @entity1 were evaluated by a psychiatrist and were blindly assessed by a neurologist with an array of scales. @entity1 on @entity9021 (n = 9) showed a significant improvement over time in the total Unified @entity191 Rating Scale score (UPDRS) (part II + part III) (P = 0.004) and in the UPDRS subscore part III (P = 0.003). None of these scores changed over time in the @entity905 group (n = 7). Both, @entity9021 and @entity905 were equally effective as antidepressants: Beck Depression Inventory scores significantly improved (P < 0.001), with no significant differences between treatment groups (P = 0.97). If our results can be confirmed in a larger clinical trial, @entity9021 ought to be considered over @entity905 given its secondary beneficial effects regarding the reduction of extrapyramidal symptoms in @entity308 @entity1 .
